Skip to main content

Trevena, Inc. (TRVN)

NASDAQ: TRVN · Delayed Price · USD
0.750
0.070 (10.29%)
At close: Dec 8, 2021 4:00 PM
0.740
-0.010 (-1.333%)
After-hours:Dec 8, 2021 7:06 PM EST
Market Cap123.39M
Revenue (ttm)637,000
Net Income (ttm)-49.51M
Shares Out164.52M
EPS (ttm)-0.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,949,524
Open0.681
Previous Close0.680
Day's Range0.681 - 0.760
52-Week Range0.630 - 3.100
Beta2.23
AnalystsBuy
Price Target4.67 (+522.7%)
Earnings DateNov 15, 2021

About TRVN

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agon...

IndustryBiotechnology
IPO DateJan 31, 2014
CEOCarrie Bourdow
Employees25
Stock ExchangeNASDAQ
Ticker SymbolTRVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Trevena stock is "Buy." The 12-month stock price forecast is 4.67, which is an increase of 522.67% from the latest price.

Price Target
$4.67
(522.67% upside)
Analyst Consensus: Buy

News

Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Trevena Reports Third Quarter 2021 Results

-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets

3 weeks ago - GlobeNewsWire

Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team

Patricia Drake appointed new Chief Commercial Officer Patricia Drake appointed new Chief Commercial Officer

3 weeks ago - GlobeNewsWire

Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021

Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET

1 month ago - GlobeNewsWire

Earnings Preview: Trevena (TRVN) Q3 Earnings Expected to Decline

Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021

Posters highlight safety and tolerability data in two complex patient populations at higher risk for adverse events Posters highlight safety and tolerability data in two complex patient populations at h...

1 month ago - GlobeNewsWire

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Other symbols:ABUSADVMKLDOMNKD
2 months ago - PennyStocks

Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients

Trevena Inc (NASDAQ: TRVN) has announced data from 30 patients enrolled in the proof-of-concept study of TRV027 in hospitalized COVID-19 patients.  The results showed that TRV027 was well-tolerated and ...

2 months ago - Benzinga

Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients

-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality

2 months ago - GlobeNewsWire

Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit

CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cent...

2 months ago - GlobeNewsWire

Imvax Appoints John M. Limongelli as Chief Legal Officer

PHILADELPHIA--(BUSINESS WIRE)--Imvax announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021.

2 months ago - Business Wire

Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021

CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen...

3 months ago - GlobeNewsWire

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients

3 months ago - GlobeNewsWire

New Strong Sell Stocks for August 20th

ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.

Other symbols:ADXNCSSEHSDTLYRA
3 months ago - Zacks Investment Research

Trevena (TRVN) Reports Q2 Loss, Misses Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of -12.50% and -85.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Trevena: Q2 Earnings Insights

Shares of Trevena (NASDAQ:TRVN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 50.00% over the past year to ($0.09), which missed t...

3 months ago - Benzinga

Trevena Reports Second Quarter 2021 Results

Company reaffirms YE goal of 100 formulary wins

3 months ago - GlobeNewsWire

Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy

Exploratory analysis shows OLINVYK treated patients are ~50% less likely to experience an AE compared to morphine patients at equivalent levels of analgesia Exploratory analysis shows OLINVYK treated pa...

3 months ago - GlobeNewsWire

Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021

Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ET Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ET

4 months ago - GlobeNewsWire

Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19

TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC) TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medica...

4 months ago - GlobeNewsWire

Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead ...

Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Reduction...

4 months ago - GlobeNewsWire

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

4 months ago - GlobeNewsWire

Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmace...

Nhwa is conducting and funding this study to support NDA regulatory filing in China

5 months ago - GlobeNewsWire

Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects

-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function

5 months ago - GlobeNewsWire

All You Need to Know About Trevena (TRVN) Rating Upgrade to Buy

Trevena (TRVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5 months ago - Zacks Investment Research